Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgery, Graduate School of Medicine, Gunma University, Maebashi, Japan.
Department of Innovative Cancer Immunotherapy, Graduate School of Medicine, Gunma University, Maebashi, Japan.
J Hepatobiliary Pancreat Sci. 2022 Sep;29(9):964-973. doi: 10.1002/jhbp.1164. Epub 2022 May 20.
The ratio of creatinine and cystatin C estimated glomerular filtration rates (eGFRcre/eGFRcys) is significantly positively correlated with sarcopenia. However, there are no published reports on the relationship between eGFRcre/eGFRcys and long-term prognosis in patients after hepatic resection for hepatocellular carcinoma (HCC).
A total of 157 patients who had undergone curative hepatic resection for HCC were retrospectively reviewed. Cystatin C levels were measured in serum samples that had been frozen after collection at surgery. We aimed to investigate the significance of cystatin C in prognostic value following hepatic resection for HCC.
The best cut-off eGFRcre/eGFRcys value for overall survival after hepatic resection for HCC was 1.0025. High eGFRcre/eGFRcys was significantly associated with poor liver function, low skeletal muscle mass, large tumor size, large ascitic volume, worse overall and recurrence-free survival. The eGFRcre/eGFRcys was significantly related to severe recurrence patterns (multiple liver recurrences, distant metastasis).
Preoperative eGFRcre/eGFRcys can predict overall and recurrence-free survival in HCC patients undergoing hepatic resection. The eGFRcre/eGFRcys is a simple and reliable surrogate marker that indicates eligibility for hepatic resection for HCC.
肌氨酸酐和胱抑素 C 估计肾小球滤过率(eGFRcre/eGFRcys)比值与肌肉减少症显著正相关。然而,目前尚无关于肝切除术后 HCC 患者 eGFRcre/eGFRcys 与长期预后之间关系的报告。
回顾性分析了 157 例接受根治性肝切除术治疗 HCC 的患者。在手术采集后将血清样本冷冻,以测量胱抑素 C 水平。我们旨在研究胱抑素 C 在 HCC 肝切除术后预后中的意义。
肝切除术后 HCC 总生存的最佳 eGFRcre/eGFRcys 截断值为 1.0025。高 eGFRcre/eGFRcys 与肝功能不良、骨骼肌量低、肿瘤大、大量腹水、总体和无复发生存差显著相关。eGFRcre/eGFRcys 与严重的复发模式(多发肝复发、远处转移)显著相关。
术前 eGFRcre/eGFRcys 可预测 HCC 患者肝切除术后的总生存和无复发生存。eGFRcre/eGFRcys 是一种简单可靠的替代标志物,可用于预测 HCC 患者的肝切除。